These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014).
    Author: Sader HS, Castanheira M, Farrell DJ, Flamm RK, Jones RN.
    Journal: Diagn Microbiol Infect Dis; 2015 Dec; 83(4):389-94. PubMed ID: 26162518.
    Abstract:
    A total of 6910 Enterobacteriaceae with inducible AmpC β-lactamases and 5328 Pseudomonas aeruginosa were collected from 71 US hospitals in 2011-2014 and were susceptibility tested using the reference broth microdilution method. Ceftazidime-avibactam demonstrated potent in vitro activity against all 3 Enterobacteriaceae genus groups evaluated, with MIC(50)/MIC(90) values of 0.12/0.5 μg/mL for Enterobacter spp. and Serratia marcescens and 0.12/0.25 μg/mL for Citrobacter spp. (99.8-99.9% susceptibility rates at ≤8 μg/mL). Furthermore, 99.3% of ceftazidime-nonsusceptible Enterobacteriaceae isolates (1015 of 1022) were susceptible to ceftazidime-avibactam (MIC(50)/MIC(90) of 0.25-0.5/1-2 μg/mL), whereas susceptibility rates for cefepime ranged from 45.9% (Citrobacter spp.) to 80.0% (S. marcescens). Ceftazidime-avibactam was also very active against P. aeruginosa (MIC(50)/MIC(90), 2/4 μg/mL; 96.8% inhibited at ≤8 μg/mL). P. aeruginosa susceptibility rates to other antipseudomonal β-lactams ranged from 79.6% for piperacillin-tazobactam to 84.5% for cefepime. Ceftazidime-avibactam inhibited 67.4% of isolates at ≤8 μg/mL (MIC(50)/MIC(90), 8/32 μg/mL) that were nonsusceptible to ceftazidime, cefepime, piperacillin-tazobactam, and meropenem.
    [Abstract] [Full Text] [Related] [New Search]